Raffit Hassan, MD
The investigational antibody-drug conjugate (ADC) anetumab ravtansine showed promising antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors, according to findings from a phase I study published in the Journal of Clinical Oncology.
“Anetumab ravtansine is being investigated as a potential treatment option for patients with mesothelin-expressing solid tumors, who currently have very limited treatment options. This phase I study showed that anetumab ravtansine was well tolerated in these patients, leading to the initiation of several phase II studies across multiple tumor types including mesothelioma, non–small cell lung cancer, cholangiocarcinoma, and pancreatic adenocarcinoma,” Hassan et al wrote in their conclusion.
Hassan R, Blumenschein Jr GR, Moore KN, et al. First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors [published online March 26, 2019]. J Clin Oncol. doi: https://doi.org/10.1200/JCO.19.02085
... to read the full story